

African Journal of Pharmacy and Pharmacology

Volume 9 Number 16, 29 April, 2015
ISSN 1996-0816



ABOUT AJPP

The **African Journal of Pharmacy and Pharmacology (AJPP)** is published weekly (one volume per year) by Academic Journals.

African Journal of Pharmacy and Pharmacology (AJPP) is an open access journal that provides rapid publication (weekly) of articles in all areas of Pharmaceutical Science such as Pharmaceutical Microbiology, Pharmaceutical Raw Material Science, Formulations, Molecular modeling, Health sector Reforms, Drug Delivery, Pharmacokinetics and Pharmacodynamics, Pharmacognosy, Social and Administrative Pharmacy, Pharmaceutics and Pharmaceutical Microbiology, Herbal Medicines research, Pharmaceutical Raw Materials development/utilization, Novel drug delivery systems, Polymer/Cosmetic Science, Food/Drug Interaction, Herbal drugs evaluation, Physical Pharmaceutics, Medication management, Cosmetic Science, pharmaceuticals, pharmacology, pharmaceutical research etc. The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in AJPP are peer-reviewed.

Submission of Manuscript

Submit manuscripts as e-mail attachment to the Editorial Office at: ajpp@academicjournals.org. A manuscript number will be mailed to the corresponding author shortly after submission.

The African Journal of Pharmacy and Pharmacology will only accept manuscripts submitted as e-mail attachments.

Please read the **Instructions for Authors** before submitting your manuscript. The manuscript files should be given the last name of the first author.

Editors

Sharmilah Pamela Seetulsingh- Goorah

*Associate Professor,
Department of Health Sciences
Faculty of Science,
University of Mauritius,
Reduit,
Mauritius*

Himanshu Gupta

*University of Colorado- Anschutz Medical Campus,
Department of Pharmaceutical Sciences, School of
Pharmacy Aurora, CO 80045,
USA*

Dr. Shreesh Kumar Ojha

*Molecular Cardiovascular Research Program
College of Medicine
Arizona Health Sciences Center
University of Arizona
Tucson 85719, Arizona,
USA*

Dr.Victor Valenti Engracia

*Department of Speech-Language and
Hearing Therapy Faculty of Philosophy
and Sciences, UNESP
Marilia-SP, Brazil.*

Prof. Sutiak Vaclav

*Rovníková 7, 040 20 Košice,
The Slovak Republic,
The Central Europe,
European Union
Slovak Republic
Slovakia*

Dr.B.RAVISHANKAR

*Director and Professor of Experimental Medicine
SDM Centre for Ayurveda and Allied Sciences,
SDM College of Ayurveda Campus,
Kuthpady, Udupi- 574118
Karnataka (INDIA)*

Dr. Manal Moustafa Zaki

*Department of Veterinary Hygiene and Management
Faculty of Veterinary Medicine, Cairo University
Giza, 11221 Egypt*

Prof. George G. Nomikos

*Scientific Medical Director
Clinical Science
Neuroscience
TAKEDA GLOBAL RESEARCH & DEVELOPMENT
CENTER, INC. 675 North Field Drive Lake Forest, IL
60045
USA*

Prof. Mahmoud Mohamed El-Mas

Department of Pharmacology,

Dr. Caroline Wagner

*Universidade Federal do Pampa
Avenida Pedro Anunciação, s/n
Vila Batista, Caçapava do Sul, RS - Brazil*

Editorial Board

Prof. Fen Jicai

School of life science, Xinjiang University, China.

Dr. Ana Laura Nicoletti Carvalho

Av. Dr. Arnaldo, 455, São Paulo, SP, Brazil.

Dr. Ming-hui Zhao

*Professor of Medicine
Director of Renal Division, Department of Medicine
Peking University First Hospital
Beijing 100034
PR. China.*

Prof. Ji Junjun

Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, China.

Prof. Yan Zhang

*Faculty of Engineering and Applied Science,
Memorial University of Newfoundland,
Canada.*

Dr. Naoufel Madani

*Medical Intensive Care Unit
University hospital Ibn Sina, Univesity Mohamed V
Souissi, Rabat,
Morocco.*

Dr. Dong Hui

Department of Gynaecology and Obstetrics, the 1st hospital, NanFang University, China.

Prof. Ma Hui

School of Medicine, Lanzhou University, China.

Prof. Gu HuiJun

School of Medicine, Taizhou university, China.

Dr. Chan Kim Wei

*Research Officer
Laboratory of Molecular Biomedicine,
Institute of Bioscience, Universiti Putra,
Malaysia.*

Dr. Fen Cun

Professor, Department of Pharmacology, Xinjiang University, China.

Dr. Sirajunnisa Razack

Department of Chemical Engineering, Annamalai University, Annamalai Nagar, Tamilnadu, India.

Prof. Ehab S. EL Desoky

Professor of pharmacology, Faculty of Medicine Assiut University, Assiut, Egypt.

Dr. Yakisich, J. Sebastian

*Assistant Professor, Department of Clinical Neuroscience R54
Karolinska University Hospital, Huddinge
141 86 Stockholm ,
Sweden.*

Prof. Dr. Andrei N. Tchernitchin

*Head, Laboratory of Experimental Endocrinology and Environmental Pathology LEEPA
University of Chile Medical School,
Chile.*

Dr. Sirajunnisa Razack

*Department of Chemical Engineering,
Annamalai University, Annamalai Nagar, Tamilnadu, India.*

Dr. Yasar Tatar

*Marmara University,
Turkey.*

Dr Nafisa Hassan Ali

*Assistant Professor, Dow institute of medical technology
Dow University of Health Sciences, Chand bbi Road, Karachi,
Pakistan.*

Dr. Krishnan Namboori P. K.

*Computational Chemistry Group, Computational Engineering and Networking,
Amrita Vishwa Vidyapeetham, Amritanagar, Coimbatore-641 112
India.*

Prof. Osman Ghani

*University of Sargodha,
Pakistan.*

Dr. Liu Xiaoji

*School of Medicine, Shihezi University,
China.*

ARTICLE

Research Article

In vitro and in vivo antiplasmodial activity of extracts of selected Kenyan medicinal plants

500

P. Jeruto, R. M. Nyangacha and C. Mutai

Full Length Research Paper

***In vitro* and *in vivo* antiplasmodial activity of extracts of selected Kenyan medicinal plants**

P. Jeruto^{1*}, R. M. Nyangacha² and C. Mutai³

¹University of Eldoret, School of Science, Department of Biological Sciences, Po Box 1125-30100, Eldoret, Kenya.

²Centre for Traditional Medicine and Drug Research, Kenya Medical Research Institute, P.O. Box 54840-00200, Nairobi, Kenya.

³Masinde Muliro University of Science and Technology, School of Public Health, Biomedical Sciences and Technology, P.O. Box 190-50100, Kakamega.

Received 16 September, 2013; Accepted 14 February, 2015

Malaria is one of the most important parasitic diseases in the world. It remains a major public health problem in Africa and is responsible for the annual death of over one million children below the age of five years. The *Plasmodium falciparum* is the most widespread etiological agent for human malaria and has become increasingly resistant to standard antimalarial drugs. Therefore, this necessitates a continuous effort to search for new drugs, particularly with novel modes of action. The medicinal plants have invariably been a rich source for new drugs and some antimalarial drugs in use today (quinine and artemisinin) were either obtained from plants or developed using their chemical structures as templates. The aim of the study was to screen seven selected medicinal plants from Kenya for antimalarial activity. 21 extracts from seven plants, were selected for *in vitro* antimalarial screening out of which 10 extracts with good activity *in vitro* were tested further in a mouse model. *In vitro* antiplasmodial testing was done by measuring the ability of the test sample to inhibit the incorporation of radio-labelled hypoxanthine into the malaria parasite. *In vivo* bioassay was done in mice using Peter's 4-days suppressive test. From the results achieved, 10 out of the 21 extracts tested, exhibited antiplasmodial activity, with IC_{50} values ranging from 6.93 to 88.4 $\mu\text{g/ml}$. When tested *in vivo*, one of the extracts had high activity with chemo suppression of 82.17%, while the rest ranged between 39.93 and 61.86%. The activities observed especially with the methanol extracts indicate that these plants deserve to be investigated further as potential antimalarial agents.

Key words: Malaria, antimalarial drugs, medicinal plants, *Plasmodium falciparum*.

INTRODUCTION

Malaria is one of the major threats concerning world public health. There are around 250 million clinical cases every year and almost one million deaths, mostly

children, which are attributable to this disease (WHO, 2008). The main reasons that explain this worsening situation are therapy problems: resistance to the current

*Corresponding author. E-mail: pasjeru@yahoo.com or pasjeru@gmail.com. Tel: (254)(020) 326629.

Author(s) agree that this article remain permanently open access under the terms of the [Creative Commons Attribution License 4.0 International License](http://creativecommons.org/licenses/by/4.0/)

antimalarial drugs, unavailability and unaffordability of antimalarial drugs and lack of new therapeutic targets (Muregi et al., 2003). Plants have invariably been a rich source for new drugs and some antimalarial drugs in use today (quinine and artemisinin) were either obtained from plants or developed using their chemical structures as templates (Gessler et al., 1994). It is already estimated that 122 drugs from 94 plant species have been discovered through ethnobotanical leads (Fabricant and Farnsworth, 2001). Plants commonly used in traditional medicine are assumed to be safe due to their long usage in the treatment of diseases according to knowledge accumulated over centuries. Therefore, the search for new drugs through the evaluation and validation of traditional medicines offers a good opportunity for the discovery and development of better medicines. Today, many pharmacological classes of drugs contain a natural product prototype. Morphine one of the best painkillers was isolated from *Papaver somniferum*, aspirin an analgesic and anticoagulant from the willow bark, warfarin an anticoagulant from *Melilotus officinalis*, Metformin the current gold standard for management of type 2 diabetes from *Galega officinalis*, quinine from *Cinchona ledgeria* and artemisinin currently the most potent antimalarial drug from *Artemisia annua* (Gilani and Rahman, 2005; Bailey et al., 2007; Gathirwa et al., 2011). Similarly, the *in vivo* antimalarial properties of several plant extracts have been studied in mice (Andrade-Neto et al., 2003). Following this trend, this study presents the results obtained from the evaluation of the *in vitro* and *in vivo* antiplasmodial activity of seven medicinal plants, namely, *Clerodendrum myricoides*, *Clusia abyssinica*, *Asparagus racemosus*, *Asparagus remota*, *Carpobrotus edulis*, *Satyrium princeae* and *Leucas calostachys*. These medicinal plants are commonly used in Nandi community in Kenya. Cytotoxicity on human fibroblasts was also evaluated in order to determine the selectivity of antimalarial action.

MATERIALS AND METHODS

Plant collection and preparation

The seven medicinal plants were selected on the basis of their traditional reputation to treat fevers or malaria locally. The plants were collected in Aldai division, Nandi County in March 2006. Permission for a sustainable plant harvesting was obtained from the Kenya Wildlife Services in the forest reserves, and from the local communities outside the forest area. The plant specimens were identified and authenticated and voucher specimens deposited at the Botanical Garden Herbarium of Maseno and East African Herbarium, National Museum of Kenya. *C. myricoides* (PJ/AL/03/06/01), *C. abyssinica* (PJ/AL/03/06/02), *A. racemosus* (PJ/AL/03/06/03), *A. remota* (PJ/AL/03/06/04), *C. edulis* (PJ/AL/03/06/05), *S. princeae* (PJ/AL/03/06/06), and *L. calostachys* (PJ/AL/03/06/07).

The plant parts were air-dried at room temperature under shade for 14 days and pulverized using a laboratory mill (Christy and Norris Ltd., Chelmsford, England) at the Center for Traditional Medicine and Drug Research, Kenya Medical Research Institute.

The resulting powders were packed in air tight polythene bags, labeled and stored in the dark until used.

Plant extractions

The plant material (50 g) was extracted at room temperature with chloromethane and methanol for 24 h each. The resulting extracts were filtered and concentrated under reduced pressure *in vacuo* to yield chloromethane extract and methanol extract. Another 50 g of the same sample was extracted once with 500 ml of distilled water in a water bath at 60°C for 1 h, filtered and lyophilized in a freeze dryer. The dry extracts for all the samples similarly treated were weighed into airtight containers and stored at 4°C until used.

In vitro antiplasmodial testing

The Sierra Leonean CQ sensitive (D6) and Indochinese CQ-resistant (W2) *Plasmodium falciparum* strains were used in this study. The parasite cultures were donated by the Malaria Research and Reference Reagent Resource Center (MR4), Manassas, Virginia, USA. Parasite cultivation was carried out using previously described procedures (Trager and Jensen, 1976; Schlichtherle et al., 2000). Cultures were maintained in RPMI 1640 culture medium (10.4 g/L) powdered medium without PABA and lactic acid (LA) dissolved in 960 ml of double distilled autoclaved water (DDAW), supplemented with 10% human serum, 25 mM (5.94 g/L) HEPES and 25 mM NaHCO₃. Human O+ red blood cells served as the parasites host cells. Test samples were prepared by dissolving in 100% dimethyl sulfoxide (DMSO) and diluting in RPMI to lower the concentration of DMSO to ≤1%. Stock solution (1 µg/ml) of chloroquine was also prepared for use as the reference drug. Semi-automated micro dilution assay technique that measures the ability of the extracts to inhibit the incorporation of [G-3H] hypoxanthine (Amersham International, Buckinghamshire, UK) into the malaria parasite was used in testing antiplasmodial activity (Desjardins et al., 1979). Aliquots (50 µl) of the test solutions were added in the first wells of 96 well flat bottomed micro culture plates (Costar Glass Works, Cambridge, UK) in duplicate and serially diluted down the plate using a Titertek motorized hand diluter (Flow Laboratories, Uxbridge, UK). The last row of wells did not contain the test samples and served as the controls. Two hundred microliters of malaria parasite culture was added into each well. The set plates were incubated at 37°C in a gas mixture 3% CO₂, 5% O₂ and 92% N₂ for 48 h, after which each well was pulsed with 25 µl of culture medium containing 0.5 µCi of [G-3H] hypoxanthine. The plates were incubated for a further 18 h. The contents of each well were then harvested onto glass fiber filter mats, washed thoroughly with distilled water, dried and the radioactivity in counts per minute (cpm) measured using a beta-counter (Wallac Micro Beta Trilux). The cpm obtained were then used to compute the IC₅₀ values as described by Sixsmith et al. (1984).

In vivo antimalarial testing

Male albino mice (6 to 8 weeks old, weighing 20±2 g) were used in the experiment. The mice were housed in standard macrolon type II cages in air-conditioned rooms at 22°C, 50 to 70% relative humidity, fed with the standard diet and received water *ad libitum*. *Plasmodium berghei* strain ANKA was maintained by serial passage of infected blood through interperitoneal injection (ip). The test protocol was based on the 4-day suppressive test (Peters et al., 1975). Briefly, *P. berghei* infected blood was obtained by heart puncture, mixed with 1% (w/v) heparin in phosphate buffered saline (PBS) (1:1) and the test animals infected by interperitoneal (ip) injection with 0.2 ml (1 × 10⁷ parasitized erythrocytes). Infected mice

Table 1. The mean IC₅₀ values (X ± SD) for plants extracts against D6 µg/ml.

Plant species	IC ₅₀ (µg/ml)		
	Chloroform	Methanol	Water
C. myricoides			
Leaves	>100	19.96	>100
Rootbark	>100	10.2	>100
<i>L. calostachys</i> leaves	40.2	88.4	>100
<i>A. racemosus</i> leaves	>100	31.35	>125
C. abyssinica			
Leaves	>100	26.72	>100
Roots	>100	6.93	66.52
<i>A. remota</i> (Leaves)	>100	22.1	>100
<i>C. edulis</i> (Roots)	>100	>100	>100
<i>S. princeae</i>	>100	>100	>100

Chloroquine IC₅₀ value = 0.020 µg/ml (positive control).

were randomly selected into groups of five for one test sample and the experimental groups treated with a single dose of 800 mg/kg of the test sample in 0.2 ml by oral administration from day 0 (immediately after infection) to 3 (Gessler et al., 1995). The mice in the positive control group were given chloroquine diphosphate (dissolved in 10% tween 80) at 5 mg/kg/day orally. Those in the negative control group received the placebo (10% tween 80) at 0.2 ml/kg/day. Parasitaemia was determined on day 4 (24 h after the last treatment) by microscopic examination by counting parasites in 4 fields of ≈100 erythrocytes per view of thin blood film sampled from the tail of the experimental mouse and stained in 10% giemsa solution. The difference between the mean number of parasites per view in the negative control group (100%) and those of the experimental groups was calculated and expressed as percent parasitaemia suppression (chemo suppression) according to the formula: PS = [(A-B)/A]×100 (Tona et al., 2001), where A is the mean parasitaemia in the negative control on day 4, and B the corresponding parasitaemia in the test group. All *in vivo* experiments were repeated three times. In cases where the standard deviation (SD) was large, the experiment was repeated yet again and in some instances, outliers were not considered while computing the SD. Percentage parasitaemia was described as number of parasitized erythrocytes per 100 erythrocytes while percentage chemo suppression was taken as inhibition of parasite growth/multiplication relative to control expressed in percentage. Parasites in the negative control group were assumed to have experienced 0% chemo suppression. Chemo suppression is thus the potency of the drug to inhibit parasite growth/multiplication.

RESULTS

In vitro antiplasmodial assays

The *in vitro* activities of *L. calostachys*, *A. remota* and *A. racemosus* were within the mild activity range (20 to 100

µg/ml). *A. remota* and *A. racemosus* had only its methanol extracts showing good activity (IC₅₀=22.1 and 31.35 µg/ml).

S. princeae and *C. edulis* showed no reasonable *in vitro* activity against D₆ for all the extracts (IC₅₀ >100 µg/ml). Apart from chloroform and aqueous extracts of *A. racemosus* that showed no activity, methanol extracts was within the mild activity range.

For *A. remota*, only the methanol extracts showed mild activity of IC₅₀=22.1 µg/ml, whereas the rest were inactive. Methanolic extracts of leaves and rootbark of *C. myricoides* showed good activity against the two isolates used. *C. abyssinica* methanolic extracts for both roots and leaves exhibited reasonable antiplasmodial activity (IC₅₀=6.93 and 26.72 µg/ml). *Ajuga* methanolic extracts also exhibited reasonable antiplasmodial activity (IC₅₀=22.1 µg/ml).

The *C. myricoides* showed good antiplasmodial activity of the methanolic extract. Although the root bark lacked activity in most of the extracts, the methanolic one gave high activity of IC₅₀ = 10.2 µg/ml for D₆ and 9.96 µg/ml for W₂, respectively which is twice as active as that of the leaves IC₅₀=19.96 and 20.58 µg/ml. This is an indication of a better *in vivo* antiplasmodial activity of the root bark than that of the leaves. There are cases in which the chloroquine-resistant isolates seemed to be more responsible to the plant extracts than the susceptible ones. For example, W₂ is more than two times susceptible than D₆ to *C. abyssinica* leaves methanolic extracts (IC₅₀=12.22 and 26.72 µg/ml, respectively).

In vivo antiplasmodial activity

Methanol extracts giving optimum antiplasmodial activity *in vitro* were subjected to further investigation in mice for antimalarial potential. Table 3 summarizes the the *in vivo* antimalarial activity of the selected plant extracts.

It was found that *C. abyssinica*, *A. racemosus* and *C. myricoides* plants used by traditional healers in Nandi district to treat malaria exhibited good *in vivo* antiplasmodial activity. The methanol extracts are the most active (Tables 1 and 2).

Parasitemia levels are increasing from day 2 to 4 (Table 3). From the chemo suppression data, it shows that parasite clearance was much pronounced on the fourth day.

DISCUSSION

In vitro antiplasmodial assays, *in vivo* antiplasmodial activity and chemo suppression results indicated that methanol extracts were very effective compared to chloroform and water extracts. This would be attributed to the fact that methanol extracts contained many of the bioactive compounds from the plant materials which acts

Table 2. The mean IC₅₀ values (X±SD) for selected plants extracts against chloroquine-resistant (W₂) *P. falciparum* isolates.

Extract	IC ₅₀ (µg/ml)	
	CQ-sensitive isolate (D ₆)	CQ-resistant isolate (W ₂)
<i>C. myricoides</i> leaves (methanol)	19.96	20.58
Root bark (methanol)	10.2	9.96
<i>C. abyssinica</i> roots (methanol)	6.93	12.22
*Chloroquine (CQ)	0.020	0.069

*Positive control.

Table 3. *In vivo* anti-malarial activity of selected medicinal plant extracts on *Plasmodium berghei* in mice.

Plant	Extract	Parasite density (%)	Chemo suppression (%)
<i>Clusia abyssinica</i> leaves	Methanol	24.03	42.10
<i>Clusia abyssinica</i> roots	Methanol	24.93	39.93
<i>Asparagus racemosus</i> leaves	Methanol	19.07	54.05
<i>Clerodendrum myricoides</i> leaves	Methanol	7.4	82.17
<i>Clerodendrum myricoides</i> root	Methanol	15.83	61.86

on the plasmodia parasites. The major ingredients known to occur in most medicinal plants are the alkaloids, terpenoids and flavonoids, whose presences is attributed to the antimicrobial activity in plants (Nostros et al., 2000). The concentrations and proportions of the active compounds in plant extracts components depend on the plant variety, origin, time of harvest, solvent used, conditions of processing and storage (Deans and Ritchie, 1987). This agrees with the ethnobotanical uses of the plants among the people of Aldai Division of Nandi County (Jeruto et al., 2008).

The methanolic root extract of *C. myricoides* showing good antiplasmodial activity for both D₆ (IC₅₀ = 10.2 µg/ml) and W₂ (9.96 µg/ml) is supported by the fact that root bark act as reservoirs for photosynthates or exudates (Balick and Cox, 1996); hence, containing many phytochemicals whose presences is attributed to the antiplasmodial activity in plants. In cases in which the chloroquine resistant isolates seemed to be more responsive to the plant extracts than the susceptible ones, it suggests lack of cross-resistance with chloroquine probably due to differences in the mode of action of compounds present in the extracts. This indicates that the extracts from these plants have the potential of solving the problem of multi-drug resistance. These plants warrant further detailed biological and chemical studies. The bioactive principles could be isolated from these plants and used to develop cheap anti-malarial drugs. *C. myricoides* has also been reported to be useful in the management of other parasitic diseases such as theileriosis (Baerts and Lehman, 1991; Muregi et al., 2004). Phytochemical investigations in the genus *Clerodendrum* has revealed macrocylic alkaloids

(Muregi et al., 2004) triterpenoids saponins (Toyota et al., 1990) and iridoid glycosides (Calis et al., 1994) with no indications of their antiplasmodial activity.

Ajuga methanolic extracts exhibiting reasonable antiplasmodial activity would be supported by previous bioassay guided phytochemical investigations that showed cardio tonic (Kuria and Muriuki, 1984) and antiplasmodial activities due to the presence of egosterols-5, 8- peroxide (Kuria et al., 2002).

Lack of *in vitro* antiplasmodial activity on *C. edulis* and *S. princeae* may not necessarily imply the same *in vivo* since compounds may either act as prodrugs, febrifuges (fever is one of the symptoms associated with a complicated severe *P. falciparum* malaria) or immunomodulators (Muregi, 2004). Active compounds isolated were from the bark of *Melia azedarach* and *Azadirachta indica* which have been found to be antiplasmodial compounds (Khalid et al., 1989). The results showed that the methanol extracts of the species *C. abyssinica*, *A. racemosus* and *C. myricoides* commonly used by traditional healers and the people of Aldai Division of Nandi South District, Nandi County (Jeruto et al., 2008) for the treatment of malaria, exhibited the highest *in vivo* antiplasmodial activity.

Rather low *in vitro* antiplasmodial activity was recorded in the other plants despite the fact that they have been used as traditional antimalarials for centuries. One probable explanation of their popular use in the treatment of malaria could be that they may be useful in managing other manifestations associated with malaria rather than therapeutic (anti-parasitic) activity. These would include reducing fever, convulsions and headache and possibly even immunostimulatory effects (Rasoanaivo et al., 1998).

Several synthetic molecules have been shown to restore CQ-sensitivity in resistant *P. falciparum* (Oduola et al., 1998). Little is known about the mechanism of the reversal of resistance by herbal remedies. Rasoanaivo et al. (1998) have investigated several medicinal plants used in association with chloroquine by local populations in Madagascar. They have shown that not only do the crude alkaloids significantly enhance the *in vitro* and *in vivo* chloroquine action but also the isolated compounds reverse resistance significantly.

The chemo suppression data showed that parasite clearance was much more pronounced on the fourth day. This may be attributed to high drug concentration in the blood due to repeated dosing and the drug has gained access into the parasites and exhibiting its effects.

CONCLUSION AND RECOMMENDATIONS

The fact that the plants screened *in vitro* had some level of antiplasmodial activity would justify their ethno pharmacological uses as traditional antimalarials. The activities observed especially with the methanol extracts indicate that these plants deserve to be investigated further as potential antimalarial agents. It is necessary to carry out detailed phytochemical studies to identify the active constituents in these plants. There are cases where the individual isolated compounds may not inhibit activity unlike their combinations in the crude extracts. This may be explained by synergistic effects of the constituents of the crude extracts or presences of prodrugs. It has been found that some plant extracts may show *in vitro* activity and no *in vivo* activity or vice versa (Gessler et al., 1995). This therefore calls for detailed *in vitro* and *in vivo* investigations of the crude extracts and the isolated compounds. Many communities around the world use these plants as traditional antimalarials (Njoroge and Bussman, 2006). Besides the presence of bioactive compounds, it also depends on many factors such as the season in which the plants is collected, the age of the plants, interspecies variation, part collected, soil and climate among others. Therefore, lack of *in vitro* antiplasmodial activity in this case does not disqualify the use of these plants as traditional antimalarials. All the three plant materials tested for bioassay contained phenolic compounds. It is not yet certain at this point that these phenolics compounds contribute to antimalarial activity. On the other hand, the root extracts contain alkaloids, and the well-known antimalarial, plant origin e.g. quinine, are alkaloids. However, it is worth noting that the plant materials that contain alkaloids also contained terpenoids (Nostros et al., 2000). This is noteworthy because the newer antimalarial compounds, such as quinghaosu, which is already in clinical use, and the quassinoids, are terpenoids.

Further toxicity studies (acute, chronic and cytotoxicity on cells) should be carried out on the crude active fractions to establish their safe levels for use by humans.

This should help in calculation of the safety dosage required for parasite clearance. The dosage if calculated would help in improving the safety of *A. racemosus*; *C. myricoides* and *C. abyssinica* based herbal drugs for malarial treatment.

Plants that exhibited moderate *in vivo* antiplasmodial activity in this research need further biochemical investigations. Drug interaction studies to be carried out so that the crude preparation and isolated compounds could be used in combination with chloroquine against resistant strains of *P. falciparum*.

Conflict of interest

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

The authors would like to thank the people of Aldai Division for sharing their indigenous knowledge, Kemri-Kenya the Centre for Microbiology Research and the Centre for Traditional Medicine and Drugs Research for their support to carry out this laboratory work.

REFERENCES

- Andrade-Neto VF, Brandao MGL, Stehmann JR, Oliveira LA, Krettli AU (2003). Antimalarial activity of *Cinchona*- like plants used to treat fever and malaria in Brazil. *J. Ethnopharmacol.* 87:253-256.
- Baerts M, Lehman J (1991). Plantes Medicinales Vétérinaires de la Région des Cretes Zaire-Ni au Burundi. *Annales Economischa Wetenschappen Koninklijk Museum voor Midden Africa* 21:133.
- Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P (2007). Metformin: the Gold Standard. A Scientific handbook. Chichester, Wiley.
- Balick M, Cox P (1996). Plants, Culture and People. Scientific American, New York.
- Calis I, Hosny M, Yuruker A (1994). Inermisnosides A and B, Two Novel Complex Iridoid Glycosides from *Clerodendrum inerme*. *J. Nat. Prod.* 57:494-500
- Deans S, Ritchie G (1987). Antibacterial properties of plant essential oils. *Int. J. Food Microbiol.* 5:165-180.
- Desjardins RE, Canfield C, Haynes J, Chulay J (1979). Quantitative assessment of anti-malarial activity *in vitro* by a semi-automated microdilution technique. *Antimicrob. Agents Chemother.* 16:710-718.
- Fabricant DS, Farnsworth NR (2001). The value of plants used in traditional medicine for drug discovery. *Environ. Health Perspect.* 109:69-75.
- Gathirwa JW, Rukunga GM, Mwitari PG, Mwikwabe MN, Muthaura CN, Kimani CW, Kiboi DM, Nyangacha RM, Omar SA (2011). Traditional herbal antimalarial therapy in Kilifi district, Kenya. *J. Ethnopharmacol.* 134:434-442.
- Gessler MC, Nkunya MHH, Mwasunmbi LB, Heinrich M, Tanner M (1994). Screening Tanzanian medicinal plants for antimalarial activity. *Acta Trop.* 56:65-77.
- Gessler MC, Tanner M, Chollet J, Nkunya MHH, Heinrich M (1995). Tanzanian medicinal plants used traditionally for the treatment of malaria: *In vivo* anti-malarial and *in vitro* cytotoxic activities. *Phytother. Res.* 9:504-508.
- Gilani AH, Rahman AH (2005). Trends in ethnopharmacology. *J. Ethnopharmacol.* 100:43-49.
- Jeruto P, Lukhoba C, Ouma G, Otieno D, Mutai C (2008). An ethno-

- botanical study of medicinal plants used by the Nandi people in Kenya. *J. Ethnopharmacol.* 116(1):370-376.
- Khalid SA, Duddeck Gonzalez-Siena HM (1989). Isolation and Characterization of the Antimalarial Agents of the Neem Tree *Azadiracta indica*. *J. Nat. Prod.* 52:922-927
- Kuria KAM, Muriuki G (1984). A New Cardiotonic Agent From *Ajuga remota* Benth. (Labiatae). *East Afr. Med. J.* 61:533-537.
- Kuria KAM, Chepkwony H, Govaerts C (2002). The Antiplasmodial Activity of Isolates From *Ajuga remota*. *J. Nat. Prod.* 65:789-793.
- Muregi FW, Chhabra SC, Njagi ENM, Lang'at-Thoruwa CC, Njue WM, Orago ASS, Omar SA, Ndiege IO (2003). *In vitro* antiplasmodial activity of some plants used in Kisii, Kenya against malaria and their chloroquine potentiation effects. *J. Ethnopharmacol.* 84:235-239.
- Muregi FW, Chhabra SC, Njagi ENM, Lang'at-Thoruwa CC, Njue WM, Orago ASS, Omar SA, Ndiege IO (2004). Anti-plasmodial Activity of Some Kenyan Medicinal Plants Extracts Singly and in Combination With Chloroquine. *Phytother. Res.* 18:379-384.
- Njoroge GN, Bussmann RW (2006). Herbal usage and informant consensus in ethnoveterinary management of cattle diseases among the Kikuyus (Central Kenya). *J. Ethnopharmacol.* 108(3):332-339
- Nostro A, Germano MP, D'Angelo V, Marino A, Cannatelli MA (2000). Extraction methods and bioautography for evaluation of medicinal plant antimicrobial activity. *Lett. Appl. Microbiol* 30:379-384.
- Oduola AM, Sowumi A, Milhow WK (1998). The Effects of Combining Promethazine with Chloroquine Against *Plasmodium falciparum in-vitro*. *Am J. Trop. Med. Hyg* 58:625-629
- Peters W, Portus JH, Robinson BL (1975). The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of *Plasmodium berghei* in screening for blood schizontocidal activity. *Ann. Trop. Med. Parasitol.* 69:155-171.
- Rasoanaivo P, Rafatro H, Ramanitrahasimbola D, Ratsimamanga-Urverg S (1998). Aklaloids from Madagascan Plants as Bio – chemical Tools in Drug Resistant Malaria. Proceedings of the 7th NAPRECA Symposium on Natural Products, Dares Salaam, Tanzania pp. 95-97.
- Schlichtherle M, Wahlgren M, Perlmann H, Scherf A (2000). Methods in Malaria Research. MR4/ATCC, Manassas, Virginia pp 1-74.
- Sixsmith DG, Watkins WM, Chulay JD, Spencer HC (1984). *In vitro* anti-malarial activity of tetrahydrofoliate dehydrogenase inhibitors. *Am. J. Trop. Med. Hyg.* 33:772-776.
- Tona L, Mesia K, Ngimbi NP, Chrimwami B, Cimanga OK, De Bruyne T, Pieters L, Vlietinck AJ (2001). *In-vivo* anti-malarial activity of *Cassia occidentalis*, *Morinda morindoides* and *Phyllanthus niruri*. *Ann. Trop. Med. Parasitol.* 95:47-57.
- Toyota M, Msonthi JD, Hostettman K (1990). A Molluscidal and Antifungal Triterpenoid Saponin From Roots of *Clerodendrum wildii*. *Phytochemistry* 29:2849-2851
- Trager W, Jensen JB (1976). Human malaria parasites in continuous culture. *Science* 193:673-675.
- World Health Organization (2008). World Malaria Report 2008. Geneva. Available at: http://whqlibdoc.who.int/publications/2008/9789241563697_eng.pdf?ua=1



African Journal of Pharmacy and Pharmacology

Related Journals Published by Academic Journals

- *Journal of Medicinal Plant Research*
- *African Journal of Pharmacy and Pharmacology*
- *Journal of Dentistry and Oral Hygiene*
- *International Journal of Nursing and Midwifery*
- *Journal of Parasitology and Vector Biology*
- *Journal of Pharmacognosy and Phytotherapy*
- *Journal of Toxicology and Environmental Health Sciences*

academicJournals